Secura Bio, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$1.3Mgeneral payments (2019-2025)
$11Kresearch payments (2019-2025)
1,863clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| David Sidransky | Baltimore, MD | Medical Oncology | $519,965.00 |
| Ryan Jacobs | Charlotte, NC | Hematology (Internal Medicine) | $153,620.16 |
| Kashyap Patel | Rock Hill, SC | Hematology & Oncology | $49,086.13 |
| Joshua Richter | New York, NY | Medical Oncology | $43,336.48 |
| Ralph Boccia | Bethesda, MD | Hematology & Oncology | $33,467.12 |
| Mojtaba Akhtari | Omaha, NE | Hematology & Oncology | $31,548.97 |
| Paul Richardson | Boston, MA | Hematology & Oncology | $31,330.00 |
| Susan O Brien | Orange, CA | Medical Oncology | $29,350.00 |
| Ashkan Emadi | Morgantown, WV | Hematology & Oncology | $26,565.00 |
| Matthew Davids | Boston, MA | Hematology & Oncology | $25,500.00 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.